With the kinase inhibitor field developing rapidly, novel applications beyond oncology are in hot pursuit. In addition to novel results in oncology, this conference will present developments in areas such as CNS, pain, anti-inflammatories, autoimmune diseases, cardiotoxicity, diabetes and more.
In addition, prioritizing targets has become extremely important and optimized validation and screening technologies are needed to keep up with the current pace. Key issues such as developing lead compounds, integrating chemistry and biology, using promising techniques such as fragment and structure based design as well as optimizing PK and PD and how to analyze the flood of data available will be addressed in this conference.
Take advantage of the opportunity to learn and discuss state-of-the-art projects in novel and promising areas in the field of kinase inhibitors.
Inhibition of Kinases by Deuterated Imidazole Compounds
Colin Kenyon, Group Leader, Biosciences, CSIR
Talk Title to be Announced
Kenneth Thress, Ph.D., Principal Scientist, Cancer and Infection Research, AstraZeneca
In Silico Structure Based Design of Non-ATP Competitive Kinase Inhibitors
Thomas Chan, CSO, ArQule, Inc.
Allosteric Kinase Inhibitors: Opportunities Beyond the Kinase Domain
Jeffrey Peterson, Assistant Professor, Cancer Genetics and Signaling, Fox Chase Cancer Center
A Novel Platform Based Approach to Silence Kinase Drug Targets Using Covalent Inhibitors
Juswinder Singh, Ph.D., Founder and CSO, Avila Therapeutics, Inc.
Mapping Protein Kinase Networks and Drug Interactions with Protein Microarrays and Predictive Bioinformatics
Steven Pelech, President & CSO, Medicine, Kinexus; Professor, University of British Columbia
Talk Title to be Announced
Daniel Rauh, Ph.D., Group Leader, Molecular Physiology, Chemical Genomics Centre of the Max Planck Society ( tentative)
Developing Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Greg Cuny, Ph.D., Director of Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration (LDDN), Harvard NeuroDiscovery Center
Targeting Protein Kinases in CNS Discovery
D. Martin Watterson, Ph.D., J.G. Searle Professor & Co-Director, Center for Drug Discovery & Chemical Biology, Northwestern University
How the Proteome Acts on the Genome, Causing the Heart to Fail: New Approaches for Therapeutic Intervention
Thomas Vondriska, Ph.D., Assistant Professor, Anesthesiology, Medicine & Physiology, UCLA
Oncodesign Translational Drug Discovery Process: Addressing the Innovation Needs in Oncology
Jan Hoflack, Ph.D., Vice President, Discovery, Oncodesign
Dual Jak3/Syk Inhibitors: A Novel Approach to the Treatment of Autoimmune Disease
Xavi Bartroli, Ph.D., Director, Drug Discovery, Palau Pharma
Cardiovascular Effects of the Novel Rho-Kinase Inhibitor SARr407899
Matthias Loehn, M.D., R&D TD Cardiovascular FFM, Sanofi-Aventis Deutschland GmbH
Talk Title to be Announced
Dapeng Qian, M.D., Ph.D., Senior Director, Drug Discovery, Progenics Pharmaceuticals, Inc.
Talk Title to be Announced
Ophelia Yin, Ph.D., FCP, Clinical Pharmacology Expert, Novartis Pharmaceuticals Corporation
Margit Eder, Ph.D., Conference Director
Phone: 781-972-5478, E-mail: meder@healthtech.com
For sponsorship or exhibiting information, please contact:
Jon Stroup, Manager, Business Development
Phone: 781-972-5483, E-mail: jstroup@healthtech.com